AIM ImmunoTech Inks Deal With Thermo Fisher Scientific's PPD Clinical Research Business To Design AIM's Phase 3 Study In Use Of Ampligen Drug
Benzinga Newsdesk 8 months ago
News
AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced an agreement with the PPD™ clinical research business of Thermo Fisher Scientific to design AIM's anticipated Phase 3 clinical trial in
AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced an agreement with the PPD™ clinical research business of Thermo Fisher Scientific to design AIM's anticipated Phase 3 clinical trial in the use of the Company's drug Ampligen in the treatment of late-stage pancreatic cancer.